Herceptin Subcutaneous Injection 600 mg (Trastuzumab)

Adult administration

Administer this medication 600mg every 3 weeks. No loading dose is required, and the recommended dose should be subcutaneously injected over 2-5 minutes every 3 weeks. Alternate the injections between the left and right thighs. The new injection site must be more than 2.5cm away from the site of the previous injection, and injection should not be done on skin that is red, bruised, painful, or hard. After the first injection, monitor the patient for 30 minutes, and for subsequent injections, for 15 minutes.

This medication can affect cardiac function, so caution is especially necessary for patients with heart disease or weakened heart function. It is crucial to evaluate heart status through cardiac function tests before administering this medication. During administration, regular cardiac function tests should also be conducted, and treatment may be discontinued if heart function worsens. Allergic reactions or infusion-related reactions may occur during the infusion of this medication, so patients should be monitored for a certain period after the injection. If symptoms such as difficulty breathing, hypotension, or rash occur, medical personnel should be notified immediately, and the infusion should be stopped or treatment received if necessary. Severe pulmonary adverse reactions have been reported rarely, so patients with pulmonary issues should consult a specialist before administration. Patients with hypersensitivity to this medication or severe dyspnea at rest should not receive it. Caution is required for patients who are currently using or have previously used anthracycline drugs, those with heart failure symptoms, hypertension, or coronary artery disease. During the administration of this medication, blood abnormalities such as reduced white blood cell count may frequently occur, therefore regular blood tests are necessary. Pregnant women or those who may become pregnant should use effective contraception during and for a certain period after administering this medication, and nursing mothers are advised to avoid breastfeeding. The safety and efficacy of this medication have not been established in children. Before administration, visually check whether the medication has deteriorated, store it in a refrigerator, and properly dispose of it if not used. This medication may affect the ability to drive or operate machinery, so caution is necessary if experiencing dizziness or drowsiness.

Serious side effects

• Urticaria
• severe swelling (edema)
• difficulty breathing
• respiratory distress
• wheezing
• pulmonary edema
• acute respiratory distress syndrome
• bronchospasm
• pneumonia
• pleural effusion

Mild side effects

• Skin rash
• urticaria
• fever
• increased blood pressure
• dizziness
• headache
• vomiting
• diarrhea
• loss of appetite
• weight loss

This medication should be stored in a tightly sealed container that does not allow air in and kept in a dark place that does not allow direct light. Additionally, do not freeze the medication; keep it refrigerated at temperatures between 2 and 8 degrees Celsius.

Appearance

A colorless to yellow clear or opaque liquid filled in a colorless transparent vial injection

Package unit

1 vial/box [vial (5 mL)]